# cBioPortal Usage Analysis Report

*Generated on 2025-12-19 04:13:53*

---

## Summary Statistics

- **Total Papers Analyzed**: 1721
- **Year Range**: 2022 - 2026
- **Classified from Full PDF**: 697 (40.5%)
- **Classified from Abstract Only**: 1019 (59.2%)
- **Most Common Analysis Type**: Gene expression analysis
- **Most Common Cancer Type**: Other solid tumor
- **Most Common Data Source**: TCGA

## Data Collection & Limitations

This analysis is based on papers that cite the three main cBioPortal publications:

- PMID 37668528
- PMID 23550210
- PMID 22588877

**Total citations in database**: 1,721 papers

**Important limitation**: The PubMed eutils API returns fewer citations than shown on the PubMed website. 
For example, PMID 37668528 shows 750 citations on PubMed's website but the API only returns 407 citations. 
This is a known limitation of the eutils citation indexing system. 
Our analysis is based on the subset of citations available through the API.

## Visualizations

### Usage Analysis Overview

![Usage Analysis](../plots/usage_analysis.png)

*Four-panel visualization showing analysis types, cancer types, data sources, and temporal trends.*

### Research Areas

![Research Areas](../plots/research_areas.png)

*Distribution of research areas utilizing cBioPortal.*

---

## Top Analysis Types

1. Gene expression analysis: 1315 papers
2. Survival analysis: 1010 papers
3. Mutation analysis: 877 papers
4. Pathway analysis: 796 papers
5. Multi-omics integration: 447 papers
6. Copy number analysis: 390 papers
7. Other: 190 papers
8. Drug response/resistance: 5 papers
9. Methods/Tools development: 5 papers
10. Biomarker discovery: 2 papers

## Top Cancer Types

1. Other solid tumor: 575 papers
2. Pan-cancer: 450 papers
3. Breast cancer: 305 papers
4. Lung cancer: 215 papers
5. Colorectal cancer: 166 papers
6. Glioma/Brain cancer: 122 papers
7. Prostate cancer: 114 papers
8. Leukemia/Lymphoma: 86 papers
9. Melanoma: 72 papers
10. Not specified: 50 papers

## Data Sources Used

1. TCGA: 981 papers
2. Multiple sources: 796 papers
3. Custom/Private data: 411 papers
4. Not specified: 301 papers
5. METABRIC: 66 papers
6. GENIE: 27 papers
7. MSK-IMPACT: 22 papers
8. ICGC: 11 papers
9. GEO: 2 papers
10. GTEx: 1 papers

## How cBioPortal is Being Used

1. Citation only: 1090 papers
2. Web-based analysis: 468 papers
3. Data download/export: 284 papers
4. Web-based visualization: 209 papers
5. Query interface: 11 papers
6. API access: 6 papers
7. Expression analysis: 4 papers
8. Unclear: 1 papers
9. Database/Resource: 1 papers

## cBioPortal Features Used

1. Not specified: 1194 papers
2. Query interface: 276 papers
3. Expression analysis: 267 papers
4. Download data: 212 papers
5. Survival analysis: 159 papers
6. Group comparison: 27 papers
7. Mutation Mapper: 26 papers
8. OncoPrint: 5 papers
9. Mutation analysis: 3 papers
10. Enrichment analysis: 3 papers

## Where Analysis Was Performed

1. Unclear: 1109 papers
2. External (downloaded data): 190 papers
3. cBioPortal platform: 159 papers
4. Mixed: 105 papers
5. ["Unclear"]: 79 papers
6. ["External (downloaded data)"]: 28 papers
7. ["Mixed"]: 27 papers
8. ["cBioPortal platform"]: 19 papers

## Most Frequently Queried Genes

1. TP53: 142 papers
2. KRAS: 89 papers
3. EGFR: 69 papers
4. BRAF: 61 papers
5. PIK3CA: 56 papers
6. CDKN2A: 38 papers
7. MYC: 37 papers
8. PTEN: 35 papers
9. BRCA2: 34 papers
10. BRCA1: 34 papers
11. ERBB2: 29 papers
12. ESR1: 22 papers
13. IDH1: 21 papers
14. APC: 20 papers
15. RB1: 19 papers
16. NRAS: 18 papers
17. MET: 18 papers
18. ATM: 17 papers
19. TERT: 17 papers
20. NF1: 17 papers

## Recent Papers Using cBioPortal

### The Roles of TOPK in Tumorigenesis and Development: Structure, Mechanisms, Pathways, and Therapeutic Implications. (2026.0)

- **Research Area**: ['Review/Commentary', 'Biomarker discovery']
- **Cancer Type**: ['Pan-cancer']
- **Usage**: This is a comprehensive review paper on TOPK (T-LAK cell-originated protein kinase) in cancer. While the paper discusses TOPK expression patterns, mutations, and clinical significance across various cancer types, the abstract and introduction provided do not explicitly describe how cBioPortal was used. The paper appears to synthesize data from multiple sources including TCGA to discuss TOPK's role in tumorigenesis, but specific cBioPortal usage details are not evident in the provided sections.

### EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']
- **Cancer Type**: ['Breast cancer']
- **Usage**: Based on the abstract and introduction provided, cBioPortal usage is not explicitly mentioned in these sections. The study uses Caris Life Sciences data for NGS and survival analysis, but no direct reference to cBioPortal is found in the provided text. The paper may cite cBioPortal in the full text or methods section not provided here, but from the available content, cBioPortal usage cannot be confirmed.

### Secreted frizzled-related protein 1a regulates hematopoietic development in a dose-dependent manner. (2026.0)

- **Research Area**: ['Review/Commentary']
- **Cancer Type**: ['Leukemia/Lymphoma']
- **Usage**: This paper focuses on developmental biology research using zebrafish models to study hematopoietic stem and progenitor cell (HSPC) development. The paper mentions observations in hematopoietic cancers where SFRP1 variants can promote or inhibit tumor development, but there is no explicit description of cBioPortal usage in the abstract or introduction provided. The citation appears to be contextual, relating their developmental findings to cancer biology observations.

### Cohesin mutations and chromatin changes in cancer. (2026.0)

- **Research Area**: ['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']
- **Cancer Type**: ['Pan-cancer']
- **Usage**: This is a review paper focusing on cohesin mutations across different cancer types. While the paper discusses recurrent mutations in cohesin complex genes (SMC1A, SMC3, RAD21, STAG1, STAG2) identified through cancer exome sequencing studies, the abstract and introduction do not explicitly describe direct usage of cBioPortal. The paper likely cites cBioPortal as a reference resource for cancer genomics data, but specific usage details are not provided in the available text.

### Loss of FAT1 drives cyclophosphamide resistance in breast cancer via the Wnt/Î²-Catenin pathway. (2026.0)

- **Research Area**: ['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Breast cancer']
- **Usage**: The paper mentions conducting comprehensive genomic and transcriptomic analysis to identify FAT1 as a tumor suppressor gene in breast cancer. While cBioPortal is cited, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used in the study. The research primarily focuses on patient-derived organoids (PDOs) and whole exome sequencing (WES) analysis of custom patient samples.

### A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine', 'Pathway analysis']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The paper does not explicitly describe how cBioPortal was used in the methodology. While the study analyzes mutation profiling and copy number alterations in osteosarcoma, there is no clear mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be for reference purposes or the actual usage details may be in the methods section not provided.

### Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The study used MSK-IMPACT targeted genomic sequencing panel data for 18 patients with metastatic clear-cell renal cell carcinoma. Genomic data including fraction of genome altered and CDKN2A copy number loss were correlated with disease-free survival outcomes. The analysis appears to have been performed using institutional data, likely accessed through cBioPortal infrastructure for MSK-IMPACT data.

### Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients. (2026.0)

- **Research Area**: ['Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Other solid tumor']
- **Usage**: The study used cBioPortal to access and analyze the TCGA-BLCA cohort (n=412) as a validation cohort for muscle-invasive bladder cancer. The authors likely used cBioPortal to obtain METTL3 expression data and clinical information from TCGA-BLCA to validate their findings regarding the association between METTL3 expression loss and poor survival outcomes in MIBC patients.

### Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. (2026.0)

- **Research Area**: ['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']
- **Cancer Type**: ['Lung cancer']
- **Usage**: Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental characterization of a novel NOTCH2-NTRK1 fusion gene using in vitro and in vivo models, phosphoproteomic analyses, and protein interaction studies. cBioPortal may be cited in the references but its specific use is not described in the provided text.

### Investigating the role of oncogenic FAM83A as a prognostic biomarker in lung adenocarcinoma: Insights from smoker and non-smoker cohorts. (2025.0)

- **Research Area**: ['Biomarker discovery', 'Pathway analysis']
- **Cancer Type**: ['Lung cancer']
- **Usage**: The study utilized cBioPortal to analyze the TCGA-LUAD cohort, specifically examining FAM83A amplification in lung adenocarcinoma samples. The authors used cBioPortal to assess copy number alterations and their correlation with immune cell infiltration. The platform was used to validate prognostic significance of identified meta-DEGs including FAM83A, CLDN2, CLDN18, CYP4B1, CYP4X1, HLF, and PLA2G1B in the TCGA-LUAD dataset.
